Abstract
The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3η monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.
Keywords: Immunotoxin, diphtheria toxin, cutaneous T cell lymphoma
Current Drug Targets
Title: Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma
Volume: 10 Issue: 2
Author(s): A. E. Frankel, S. L. Zuckero, A. A. Mankin, M. Grable, K. Mitchell, Y. J. Lee, D. M. Neville and J. H. Woo
Affiliation:
Keywords: Immunotoxin, diphtheria toxin, cutaneous T cell lymphoma
Abstract: The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3η monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.
Export Options
About this article
Cite this article as:
Frankel E. A., Zuckero L. S., Mankin A. A., Grable M., Mitchell K., Lee J. Y., Neville M. D. and Woo H. J., Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma, Current Drug Targets 2009; 10 (2) . https://dx.doi.org/10.2174/138945009787354539
DOI https://dx.doi.org/10.2174/138945009787354539 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
Emerging Drug Targets and Revolutionary Therapeutic Approaches for Effective Anti-Cancer Intervention
Recent advancements in cancer research have significantly advanced our understanding of the intricate molecular mechanisms driving cancer progression, leading to the identification of new drug targets and therapeutic strategies. The elucidation of complex signaling pathways and genetic aberrations associated with tumorigenesis has provided valuable insights into potential targets for intervention. ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Progress in Drug Delivery, Therapeutic Strategies, and Nursing Practices: Enhancing Diagnostics and Clinical Outcomes in Complex Diseases
The recent advancements in drug delivery systems as well as therapeutics have significantly improved therapy effectiveness combined with better patient results specifically for difficult disease management. The modern pharmaceutical research field makes drug targeting its main priority because this approach strengthens therapeutic agents' precision while improving their effectiveness. Multiple delivery ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ewing’s Sarcoma Cancer Stem Cell Targeted Therapy
Current Stem Cell Research & Therapy RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Use of Ultrasound to Observe Mycosis Fungoides: A Case Report and Review of Literature
Current Medical Imaging Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design Phytochemical and Pharmacological Overview of Triticum aestivum: An Update
Current Traditional Medicine Pharmacogenetics and the Pharmaceutical Industry
Current Pharmaceutical Design Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS)
Current HIV Research Synergistic Approaches to Clinical Oncology Biomarker Discovery
Current Topics in Medicinal Chemistry Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Anti-Cancer Agents in Medicinal Chemistry From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets The Use of TNF Family Ligands and Receptors and Agents which Modify their Interaction as Therapeutic Agents
Current Drug Targets Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Structure-based Drug Design Strategies in the Development of Small Molecule Inhibitors Targeting Bcl-2 Family Proteins
Letters in Drug Design & Discovery Currently Used Biologic Agents in the Management of Behcet’s Syndrome
Current Medicinal Chemistry Relevance of Cytochrome P450 Polymorphisms in the Treatment of Helicobacter pylori Infection and Gastroesophageal Reflux Disease
Current Pharmacogenomics Small Non-Coding RNAs as Novel Therapeutics
Current Molecular Medicine Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Anticancer Activity of New Compounds Using Benzimidazole as a Scaffold
Anti-Cancer Agents in Medicinal Chemistry Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued)